Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prosonix

- PMLiVE

Opening up innovation

Paul-Peter Tak on GlaxoSmithKline’s R&D strategy and the pivotal role of immunology

- PMLiVE

GSK’s blockbuster hopeful Shingrix filed in US

Clinical data showed shingles vaccine had 90% efficacy in elderly patients

- PMLiVE

After delay, Merck gets US approval for serious infection drug

Zinplava anticipated to accrue $300m in sales by 2020

- PMLiVE

Rigel shaken after fostamatinib misses phase III trial target

Firm will still pursue early 2017 FDA approval for the autoimmune disease therapy

- PMLiVE

Halesway changes name to FCB Halesway

Move aligns agency more closely with its parent company FCB Health

- PMLiVE

Clinical trials enter the genomic age

Looking at the factors driving this change and assessing the benefits

Bristol-Myers Squibb (BMS) building

NICE turns down Opdivo but offers CDF hope

Wants more cost-effectiveness data to be gathered

- PMLiVE

NICE rejects Imbruvica for non-Hodgkin’s lymphoma

Draft guidance cites insufficient cost-effectiveness evidence for J&J’s drug

National Institute for Health and Care Excellence NICE logo

NICE to create fast track for most cost-effective new drugs

Proposes accelerated appraisal process for drugs with QALY of £10,000 or less

- PMLiVE

Synairgen sinks as AZ halts trial of asthma drug

Results from a phase II trial of inhaled antiviral therapy set to be inconclusive

- PMLiVE

At current progress, 2025 Alzheimer’s target ‘unlikely to be reached’

Drug development and diagnosis process requires shake-up to create effective therapies

- PMLiVE

Health activators lack confidence in primary healthcare

Survey finds patient decision-makers increasingly turning to non-traditional sources

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links